Back to Medicines

Evolocumab: Injections When Statins Are Not Enough

Evolocumab: Injections When Statins Are Not Enough
Prescription Medicines Editorial 5 October 2025

Evolocumab is a monoclonal antibody that blocks PCSK9, a protein which destroys LDL receptors on liver cells. Those receptors are what pull LDL cholesterol out of the bloodstream - statins work partly by increasing them. Blocking PCSK9 means the receptors survive longer and keep clearing LDL, and the effect is large: evolocumab roughly halves LDL again on top of maximum statin treatment.

Follow the plan your specialist gave you. This guide contains no doses.

Who it is for

Evolocumab is not an alternative to a statin for ordinary cholesterol management. It is for people whose LDL remains high despite maximum tolerated treatment, and access on the NHS is through defined criteria based on LDL level and cardiovascular history:

  • Familial hypercholesterolaemia, where LDL is very high from birth
  • Established cardiovascular disease with LDL persistently above a threshold
  • Statin intolerance that is genuine and documented

The thresholds differ between those groups, and they are specific. If you are on maximum tolerated treatment and still above target, it is worth asking whether you meet them - see cholesterol numbers.

Before that point, adding ezetimibe achieves more than pushing a statin dose higher - see ezetimibe.

Establish statin intolerance properly first

Genuine statin intolerance is less common than the label suggests. Blinded trials found muscle symptoms at similar rates on statin and placebo, which means expectation contributes considerably.

A supervised trial off and back on, and a trial of a different statin at a lower dose or on alternate days, establish whether the statin is actually responsible - and frequently it is not.

That matters because statins have decades of outcome evidence behind them. See statins and muscle pain and pravastatin, which suits some people who cannot tolerate others.

What the trials found

The cardiovascular outcome trial of evolocumab in people with established atherosclerotic disease found a reduction in heart attacks, strokes and revascularisation, on top of statin treatment.

The LDL levels achieved were very low by historical standards, and no signal of harm from that emerged - which addressed a long-standing question about whether there is a floor below which lowering LDL stops being useful or starts being harmful.

Injecting it

Evolocumab is given by subcutaneous injection every two weeks, or monthly at a higher dose using a larger device.

It is injected into the abdomen, thigh or upper arm, rotating sites. Most people self-inject after training.

Store it in the fridge, and let it reach room temperature for around half an hour before injecting - cold solution stings considerably more.

See medicines that need the fridge. Used devices go in a sharps bin - see needles and sharps disposal.

Side effects

Evolocumab is unusually well tolerated. Injection site reactions - redness, pain, bruising - are the commonest, and usually mild.

Cold-like symptoms, back pain and joint aches are reported at low rates, close to placebo in trials.

Seek urgent help for swelling of the face, lips or throat, or difficulty breathing - hypersensitivity reactions are rare but possible with any antibody treatment. See anaphylaxis.

Because it is an antibody rather than a small molecule, it is not metabolised by liver enzymes and has essentially no drug interactions - a genuine advantage for anyone on a complicated list.

You still take the statin

Evolocumab is added to a statin rather than replacing it, except in people who genuinely cannot tolerate one.

Stopping the statin because the injection is working undoes part of the benefit, since the two act on the same pathway from different directions.

Inclisiran

Inclisiran works on the same target by a different mechanism - it is a small interfering RNA that silences PCSK9 production inside liver cells.

Its practical distinction is dosing: after two loading doses, it is given twice a year, usually in primary care rather than by self-injection.

Twice-yearly administration removes the adherence problem entirely, which is a substantial advantage. Its cardiovascular outcome data is less mature than evolocumab's.

Which you are offered depends on local arrangements and on the specific criteria you meet.

Familial hypercholesterolaemia

FH is an inherited condition causing very high LDL from birth and early cardiovascular disease. It is considerably under-diagnosed.

If you have very high cholesterol, particularly with a family history of heart disease before 60, ask about it - cascade testing of relatives is recommended, and identifying and treating family members early is one of the clearest wins in preventive medicine.

Pregnancy

Evolocumab is not recommended in pregnancy. Lipid-lowering treatment is generally paused before conception and during pregnancy and breastfeeding - discuss timing well in advance.

More on how the main families of medicine work in the Medicines section, including Omega-3: Supplements Versus Prescriptions.